|
Re: Entertainment During Wait
|
2
|
Resverlogix Corp.
|
Aug 25, 2017 03:24PM
|
|
Re: Enthusiasm? NOT!
|
6
|
Zenith Epigenetics
|
Oct 30, 2021 12:56PM
|
|
Re: Enthusiasm? NOT!
|
3
|
Zenith Epigenetics
|
Oct 30, 2021 06:00PM
|
|
Re: Epigenetics market size
|
3
|
Zenith Epigenetics
|
Jan 25, 2024 11:48AM
|
|
Re: Epigenetics market to reach $16.3 Billion in 6 years (article)
|
3
|
Resverlogix Corp.
|
Jan 18, 2016 05:57PM
|
|
Re: Epigenetics market to reach $16.3 Billion in 6 years (article)
|
2
|
Resverlogix Corp.
|
Jan 20, 2016 05:34PM
|
|
Re: Epigenetics: an exciting new approach in prostate cancer
|
4
|
Zenith Epigenetics
|
Apr 09, 2019 03:27PM
|
|
Re: Equity financing
|
3
|
Zenith Epigenetics
|
Jun 25, 2018 03:27PM
|
|
Re: ESC 2019 Symposium: Epigenetics: A new pathway to tackle residual risk?
|
3
|
Resverlogix Corp.
|
Jul 06, 2019 01:53PM
|
|
Re: Est. Cash Position
|
4
|
Zenith Epigenetics
|
Apr 27, 2021 10:18AM
|
|
Re: European Atherosclerosis Society Congress May 29 - June 1
|
4
|
Resverlogix Corp.
|
May 27, 2016 05:00PM
|
|
Re: Evacetrapib fails
|
2
|
Resverlogix Corp.
|
May 18, 2017 10:35AM
|
|
Re: Eversana ValuationCaseStudy
|
11
|
Resverlogix Corp.
|
Jan 08, 2022 12:52PM
|
|
Re: Eversana ValuationCaseStudy
|
6
|
Resverlogix Corp.
|
Jan 09, 2022 06:29PM
|
|
Re: Eversana ValuationCaseStudy
|
3
|
Resverlogix Corp.
|
Jan 04, 2022 01:16PM
|
|
Re: Exempt Distribution - 2022-04-14
|
6
|
Resverlogix Corp.
|
Apr 19, 2022 12:08PM
|
|
Re: Exposure in Motley Fool....
|
1
|
Resverlogix Corp.
|
Oct 08, 2019 10:10PM
|
|
Re: Exposure in Motley Fool....
|
2
|
Resverlogix Corp.
|
Oct 09, 2019 08:08AM
|
|
Re: FA expectations
|
6
|
Resverlogix Corp.
|
Sep 20, 2017 10:13AM
|
|
Re: Fabry trial news, Halifax and Alberta's Children't Hospital slated....
|
4
|
Resverlogix Corp.
|
Jun 14, 2017 03:44PM
|
